Please login to the form below

Not currently logged in
Email:
Password:

tafamidis

This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

Alnylam gets EU nod for Onpattro amid pricing backlash

s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics